Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer

Korábbi kezelés

• History of active malignant tumor within 3 years prior to initial treatment（except for the cervical cancer）and any locally curable tumors treated with radical therapy;
• Any high-risk factor confirmed by postoperative pathology: positive lymph node metastasis, positive parametrial invasion, or positive resection margin;
• History of neoadjuvant therapy prior to enrollment;
• Local recurrence or distant metastasis prior to enrollment;

Más betegség

• Severe cardiac, cerebral, hepatic, or renal disorders;
• Any other conditions deemed unsuitable for this trial by the investigator.

Egyéb

• Postoperative intestinal obstruction or intestinal adhesion;
• Long-term immunocompromised state;
• Pregnant or lactating females;
• Premature discontinuation of treatment for any reason;
• Poor compliance, unwillingness to participate, or inability to cooperate with follow-up;

• ECOG performance status 0 or 1;
• Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;
• Status post radical hysterectomy with pelvic lymph node dissection with or without para-aortic lymph node dissection, and postoperative radiotherapy initiated within 3 months;
• For squamous cell carcinoma: meeting Sedlis criteria; for adenocarcinoma and adenosquamous carcinoma: meeting the "four-factor model";
• Bone marrow function: white blood cell (WBC) count ≥3.0×10⁹/L, neutrophil count (NEUT) ≥1.5×10⁹/L, platelet count (PLT) ≥80×10⁹/L, hemoglobin (Hb) ≥90 g/L; renal function: normal or serum creatinine (SCr) ≤1.5×upper limit of normal (ULN) or creatinine clearance ≥50 ml/min; hepatic function: total bilirubin (TBIL) ≤1.5×ULN, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5×ULN;
• Voluntarily signed the informed consent form prior to study enrollment.